Get startedLog in
    Picture of Genmab A/S logo

    GMAB — Genmab A/S News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide

    Picture of Genmab A/S logoGenmab A/S
    30/06/2026 07:22
    BRIEF-Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide
    June 30 (Reuters) - Genmab A/S GMAB.CO:
    • ANNOUNCES POSITIVE PHASE 3 RESULTS FOR EPCORITAMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL
    • EPCORE DLBCL-4 REDUCES RISK OF PROGRESSION AND DEATH BY UP TO 60%
    • REPORTS PHASE 3 EPCORE DLBCL-4 TRIAL MEETS PRIMARY ENDPOINT IN R/R DLBCL
    • EPCORITAMAB PLUS LENALIDOMIDE SHOWS CONSISTENT SAFETY PROFILE
    • CO AND ABBVIE TO ENGAGE REGULATORY AUTHORITIES ON EPCORE DLBCL-4 RESULTS
    Source text: ID:nGNX3DJgj3
    Further company coverage: GMAB.CO

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Genmab A/S

    See all news